This company has been marked as potentially delisted and may not be actively trading.

NYSE:NVTA

Invitae (NVTA) Stock Price, News & Analysis

Invitae logo

About Invitae Stock (NYSE:NVTA)

Key Stats

Today's Range
$0.0003
▼
$0.0003
50-Day Range
N/A
52-Week Range
$0.02
▼
$0.02
Volume
N/A
Average Volume
23.72 million shs
Market Capitalization
$80.10 thousand
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Invitae Corporation, a medical genetics company, that provides genetic information to improve healthcare of people in the United States, Canada, and internationally. The company offers genetic tests in various clinical areas, including hereditary cancer, precision oncology, women's health, rare diseases, and pharmacogenomics; digital health solutions; and health data services. It serves patients, healthcare providers, biopharma companies, and other partners. The company was formerly known as Locus Development, Inc. and changed its name to Invitae Corporation in 2012. Invitae Corporation was incorporated in 2010 and is headquartered in San Francisco, California.

Receive NVTA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Invitae and its competitors with MarketBeat's FREE daily newsletter.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

NVTA Stock News Headlines

The investigation Porter spent tens of thousands to document
Porter Stansberry flew the Porter and Co. team 3,300 miles to Dublin to investigate a 17-year investing experiment called Project Prophet - and documented everything on film. Rooted in the laws of physics, this quantitative approach challenges conventional wealth-building wisdom. With 17 years of verified data behind it, Porter calls it unlike anything he has seen in nearly 30 years in the business.tc pixel
See More Headlines

NVTA Stock Analysis - Frequently Asked Questions

Invitae Co. (NYSE:NVTA) posted its quarterly earnings results on Tuesday, May, 9th. The medical research company reported ($0.37) EPS for the quarter, topping analysts' consensus estimates of ($0.41) by $0.04. The business's quarterly revenue was down 5.1% on a year-over-year basis.

Invitae (NVTA) raised $89 million in an initial public offering on Thursday, February 12th 2015. The company issued 6,350,000 shares at $13.00-$15.00 per share. J.P. Morgan acted as the underwriter for the IPO and Cowen and Company and Leerink Partners were co-managers.

Based on aggregate information from My MarketBeat watchlists, some other companies that Invitae investors own include NVIDIA (NVDA), CRISPR Therapeutics (CRSP), Block (XYZ), Tesla (TSLA), PayPal (PYPL), Advanced Micro Devices (AMD) and Pinterest (PINS).

Company Calendar

Today
11/17/2026
Fiscal Year End
12/31/2026

Industry, Sector and Symbol

Stock Exchange
NYSE
Industry
Medical laboratories
Sub-Industry
N/A
Current Symbol
NYSE:NVTA
CIK
1501134
Fax
N/A
Employees
1,700
Year Founded
2010

Profitability

EPS (Trailing Twelve Months)
($5.38)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$3.11 billion
Net Margins
-299.14%
Pretax Margin
-301.93%
Return on Equity
-6,100.71%
Return on Assets
-19.68%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
2.39
Quick Ratio
2.25

Sales & Book Value

Annual Sales
$481.58 million
Price / Sales
0.00
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$0.42 per share
Price / Book
0.00

Miscellaneous

Outstanding Shares
267,010,000
Free Float
284,373,000
Market Cap
$80.10 thousand
Optionable
Optionable
Beta
1.59

Social Links

 The Best Nuclear Energy Stocks to Buy Cover

Nuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.

Get This Free Report

This page (NYSE:NVTA) was last updated on 4/8/2026 by MarketBeat.com Staff.
From Our Partners